FAROPENEM SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H14NO5S.Na
Molecular Weight	307.298
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C([O-])=O

InChI

InChIKey=ICSAXRANXQSPQP-VUKDEKJYSA-M

InChI=1S/C12H15NO5S.Na/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6;/h5-7,11,14H,2-4H2,1H3,(H,16,17);/q;+1/p-1/t5-,6-,7+,11-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C12H14NO5S
Molecular Weight	284.308
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=37321
Curator's Comment: description was created based on several sources, including: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=80189 | https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054149.pdf | https://www.ncbi.nlm.nih.gov/pubmed/12886052

Faropenem is a unique antimicrobial penem being developed for oral administration. It markets it in two forms: faropenem sodium and faropenem medoxomil. The high binding affinities of faropenem to penicillin-binding proteins from gram-negative and gram-positive bacteria are mirrored by its pronounced and concentration-dependent bactericidal effect. It is usually used to treat a wide range of infections such as skin, respiratory and otorhinologic infections. The most commonly reported adverse reactions include diarrhea, abdominal pain, loose stool, rash and nausea. The FDA refused to approve faropenem – the applicant have to conduct new studies and clinical trials to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12886052	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Chronic bronchitis 52 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=37321	Curative	Approved 8583	Farom Approved Use Drug is indicated for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP).
Community-acquired pneumonia 47 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=37321 https://www.ncbi.nlm.nih.gov/pubmed/18298129	Curative	Approved 8583	Farom Approved Use Drug is indicated for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP).
Acute bacterial sinusitis 26 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=37321 https://www.ncbi.nlm.nih.gov/pubmed/18298129	Curative	Approved 8583	Farom Approved Use Drug is indicated for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP).
Skin infections 59 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=37321	Curative	Approved 8583	Farom Approved Use Drug is indicated for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS), community-acquired pneumonia (CAP) and uncomplicated skin and skin structure infections.

C_max

Value	Dose	Analyte	Population
1.32 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: CHILD sex: FEMALE / MALE food status: FED
2.08 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: CHILD sex: FEMALE / MALE food status: FED
2.36 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.24 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.37 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.9 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2.02 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1.89 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.24 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.25 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3.49 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: FED
4.25 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
4.1 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: CHILD sex: FEMALE / MALE food status: FED
5.89 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: CHILD sex: FEMALE / MALE food status: FED
3.95 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11.73 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.59 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.18 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.34 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.14 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11.73 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.75 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
16.49 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: FED
9.75 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
1.66 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: CHILD sex: FEMALE / MALE food status: FED
1.14 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: CHILD sex: FEMALE / MALE food status: FED
0.76 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.85 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.08 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.96 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.89 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.93 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.85 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.01 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1.61 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: FED
1.01 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	FAROPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
9.3% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37			FAROPENEM serum	Homo sapiens

Doses

Dose	Population	Adverse events
300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/	Disc. AE: Diarrhea, Vomiting... Other AEs: Nausea... AEs leading to discontinuation/dose reduction: Diarrhea Vomiting Other AEs: Nausea Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/

AEs

AE	Significance	Dose	Population
Nausea		300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/
Diarrhea	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/
Vomiting	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17011409/

PubMed

Title	Date	PubMed
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.	2013-06	23507276
Quinolone and cephalosporin resistance in enteric Fever.	2010-09	20927288
High-throughput determination of faropenem in human plasma and urine by on-line solid-phase extraction coupled to high-performance liquid chromatography with UV detection and its application to the pharmacokinetic study.	2010-05-01	20036477
Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.	2010-04-16	20177059
Synthesis, characterization and antibacterial activities of some new ferrocene-containing penems.	2010-03	20053481
Nationwide survey of the development of drug-resistance in the pediatric field: drug sensitivity of Haemophilus influenzae in Japan.	2009-12	20012732
Nationwide survey of the development of drug-resistant pathogens in the pediatric field: drug sensitivity of Streptococcus pneumoniae in Japan.	2009-12	20012731
Pedal oedema: a rare side-effect of faropenem.	2009-10	19796033
Streptococcus pneumoniae serotype 3 among Costa Rican children with otitis media: clinical, epidemiological characteristics and antimicrobial resistance patterns.	2009-08-14	19682369
Increase in pneumococcus macrolide resistance, United States.	2009-08	19751588
Antimicrobial development in the era of emerging resistance.	2009-07	19601889
[Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract].	2009-04	19673353
New antimicrobial molecules and new antibiotic strategies.	2009-04	19296416
Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.	2009-03	19208884
A case of multidrug-resistant Salmonella enterica serovar Typhi treated with a bench to bedside approach.	2009-02-28	19259362
The determinants of the antibiotic resistance process.	2009	21694883
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008-12	19337440
[Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases].	2008-12	19288854
[T serotypes distribution and antimicrobial susceptibility of Streptococcus pyogenes in children with pharyngotonsillitis in Asahikawa].	2008-12	19288853
Emerging therapies for the treatment of Helicobacter pylori infections.	2008-11	18845620
Region-dependent absorption of faropenem shared with foscarnet, a phosphate transporter substrate, in the rat small intestine.	2008-09	18614339
[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].	2008-08	19024644
Genetic analysis of faropenem-resistant Enterococcus faecalis in urinary isolates.	2008-04	18503200
Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.	2008-02	18246520
Faropenem medoxomil.	2008-01	18094341
Determination of faropenem in human plasma and urine by liquid chromatography-tandem mass spectrometry.	2008-01	17604362
Evaluation of the bioequivalence of two faropenem formulations in healthy Indian subjects.	2008	19202741
Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026.	2008	18298129
Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori.	2007-12	18001403
In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l.	2007-07	17512703
Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.	2007-05	17353220
Faropenem: review of a new oral penem.	2007-04	17402834
Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.	2006-12	17181408
[Relationship between protein binding and antimicrobial activities of antibiotics against Streptococcus pneumoniae and Haemophilus influenzae].	2006-10	17180806
Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis.	2006-10	17011409
Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.	2006-09	16840432
Redefining penems.	2006-03-30	16413506
JPMorgan 24th Annual Healthcare Conference.	2006-03	16523382
Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.	2005-12	16269221
[Investigation of Streptococcus pneumoniae and Haemophilus influenzae isolated from pediatric outpatients nationwide with a respiratory tract infection at the first consultation (2002-2003)--proportion of resistant strains and sensitivity to oral antibacterial agents].	2005-11	16366360
In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics.	2005-10	16258826
The antimicrobial armamentarium: evaluating current and future treatment options.	2005-10	16178676
Investigational new drugs for the treatment of resistant pneumococcal infections.	2005-08	16050791
Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.	2005-04-09	15816496
In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora.	2005-04	15763284
Mycobacterium peregrinum infection in a patient with AIDS.	2005-03	15805720
In vitro evaluation of faropenem activity against anaerobic bacteria.	2005-02	15828442
Quantification of faropenem in human plasma by high-performance liquid chromatography.	2005	16430031
The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae.	2004-10	15373892
Bacterial resistance to antimicrobials in urinary isolates.	2004-09	15364302

Patents

Sample Use Guides

In Vivo Use Guide

150 - 300 mg three times a day

Route of Administration: Oral

In Vitro Use Guide

Exposure of S. aureus to faropenem at minimum inhibitory concentrations (MICs) of 1/8 or 1/4 resulted in irregular septum formation. At 1x MIC or higher, a larger number of lysed cells were observed. Exposure of E. coli to 1/8x MIC or 1/4x MIC also induced changes in cellular shape; the normal rod-shaped form changed to a spherical form in a time-dependent manner. After exposure of E. coli to 1x MIC for 2 h, bulging-shaped E. coli cells were observed and after 4 h of exposure cell lysis was demonstrated. In the presence of 4x MIC, spheroplast-like forms and cell lysis were observed.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:36:46 GMT 2025` Edited by `admin` on `Mon Mar 31 19:36:46 GMT 2025`
Record UNII	7O46G914RQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FAROPENEM SODIUM SALT

Preferred Name

English

FAROPENEM SODIUM

Common Name

English

FAROPENEM SODIUM [MART.]

Common Name

English

WY-49605

Common Name

English

Faropenem sodium [WHO-DD]

Common Name

English

SY-5555

Common Name

English

SODIUM (+)-(5R,6S)-6-((1R)-1-HYDROXYETHYL)-7-OXO-3-((2R)-TETRAHYDRO-2-FURYL)-4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLATE

Systematic Name

English

ALP-201

Common Name

English

YM-044

Common Name

English

FAROPENEM SODIUM SALT [MI]

Common Name

English

SUN 5555

Common Name

English

FUROPENEM

Brand Name

English

FAROM

Brand Name

English

WY 49605

Common Name

English

SUN-5555

Common Name

English

SY 5555

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-((1R)-1-HYDROXYETHYL)-7-OXO-3-((2R)-TETRAHYDRO-2-FURANYL)-, SODIUM SALT (1:1), (5R,6S)-

Common Name

English

Code System Code Type Description

FDA UNII

7O46G914RQ